Zipalertinib
Zipalertinib is an investigational new drug that is being evaluated for the treatment of non-small cell lung cancer with EGFR mutations, particularly exon 20 insertion mutations.
Zipalertinib is an investigational new drug that is being evaluated for the treatment of non-small cell lung cancer with EGFR mutations, particularly exon 20 insertion mutations.